ARCAGY/ GINECO GROUP
ARCAGY/ GINECO GROUP
Explore linked clinical trials.14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib | ovarian carcinosarcoma | Recruiting | Phase 2 / Phase 3 | 2026-09-09 | NCT03651206 | |
| Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer | Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Not yet recruiting | Phase 2 | 2026-08-13 | NCT07763496 | |
| Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2026-08-04 | NCT06476184 | |
| A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS | LOCALLY ADVANCED CERVICAL CANCERS | Active, not recruiting | Phase 2 | 2026-07-30 | NCT06715241 | |
| Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. | ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status | Active, not recruiting | Phase 2 | 2026-07-24 | NCT04053322 | |
| Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-10 | NCT07637851 | |
| PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, adenosquamous carcinoma, carcinoma, cervical carcinoma, cervix disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, mixed neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2026-07-07 | NCT05581121 | |
| Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-04-13 | NCT05183984 | |
| Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2025-12-04 | NCT05201547 | |
| Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT | ovarian small cell carcinoma | Recruiting | Phase 2 | 2025-11-28 | NCT04602377 | |
| Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer | Metastatic Breast Cancer With a Isolated Brain Progression | Active, not recruiting | Phase 2 | 2025-11-17 | NCT05041842 | |
| Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Sex Cord-Gonadal Stromal Tumors, gonadal tissue neoplasm, neoplasm | Active, not recruiting | Not applicable | 2025-09-22 | NCT03418844 | |
| OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC | Adnexal Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Active, not recruiting | Phase 2 | 2024-12-02 | NCT04713514 | |
| International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Not applicable | 2024-07-08 | NCT03386734 |